ClinicalTrials.gg
CompletedNCT05048498Updated Oct 17, 2023

Pharmacokinetics, Tolerability and Safety of NEX-18a

A Phase 1 interventional study of NEX-18a injection and Azacitidine Injection in Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML), sponsored by Nanexa AB. Completed at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Nanexa AB · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
115th of 126
2 · median 38
Started
2021
with 3 others
Phase 1
30 of 130
4 open now
Registered
110th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 115th largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2021, is one of 30 in phase 1, and was the 110th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The study will evaluate the safety, tolerability and pharmacokinetics of NEX-18a, a long-acting injectable azacitidine, in patients diagnosed with intermediate 2 or higher-risk MDS, CMML, or AML and already on treatment with azacitidine.

Read the detailed description

Since 2010, subcutaneous treatment with azacitidine has been the first-line treatment for patients with high-risk MDS. Azacitidine has been established as a standard of care and is described in the National Comprehensive Cancer Network (NCCN) guidelines as a core component of optimal treatment of MDS. However, mainly due to its short half-life (41 minutes) when administered subcutaneously azacitidine should, according to the approved label, be administered for seven consecutive days at a dose of 75 mg/m2 body surface area (BSA) each 28-day cycle. In the Nordic Guidelines, two alternative dosing schedules may also be considered: 100 mg/m2 BSA sc day 1-5 or 75 mg/m2 BSA sc day 1-5 + 8-9 (to avoid injection during weekends).

Nanexa AB has developed NEX-18a, a subcutaneous injection of azacitidine with extended-release based on the drug delivery system, PharmaShell®. Drug particles are enclosed in a coating with controlled solubility, and as the coating dissolves over time the drug is released in a predefined manner. This technique provides a way to create drugs with a prolonged release for parenteral administration. The technology used by Nanexa to manufacture the coating is via Atomic Layer Deposition (ALD). In ALD, reactive gases are used which build up a surface coating with high precision, atomic layer by atomic layer.

NEX-18a will offer a benefit to current azacitidine treatment with a reduction of subcutaneous administrations, decreased need for pre-medication, and will reduce the time each patient has to spend in the hospital in order to receive the treatment in each cycle. In addition, the patients will spend less time traveling to and from the hospital and from a health care perspective, one injection instead of seven per cycle will reduce the time and the resources the health care provider dedicates to treating the patients.

03

Conditions studied

  • Myelodysplastic Syndromes (MDS)
  • Chronic Myelomonocytic Leukemia (CMML)
  • Acute Myeloid Leukemia (AML)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written prior to any study specific procedures.
  2. Female and male patients ≥ 18 years of age.
  3. (BMI) > 19 and \< 30 kg/m2 BSA at screening.
  4. Treatment with azacitidine corresponding to 100 mg/m2 BSA x 5 per treatment cycle for at least six cycles for:

    1. intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS)
    2. chronic myelomonocytic leukemia (CMML) with 10-29 % marrow blasts
    3. acute myeloid leukemia (AML) according to World Health Organization (WHO) classification
  5. (ECOG) performance status of 0, 1, or 2.
  6. Recovery of Hematology and Clin. Chemistry assessment according to clinical praxis at the start of the last azacitidine treatment cycle before the screening visit.
  7. Female subject must be of non- (defined as pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as females defined as 12 months' amenorrhoea [in questionable cases a blood sample with simultaneous follicle stimulation hormone 25-140 IE/L and estradiol \< 200 pmol/L is confirmatory])
  8. Male patients must agree to use an adequate method of . Male patients who are sexually active must use, with their partner, a condom AND one of the following methods of highly effective contraception from the time of IMP administration until 90 days after the last dose of IMP.

    1. oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable or implanted hormonal contraceptives
    2. intrauterine device
    3. intrauterine system (for example progestin-releasing coil)
    4. vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate)
    5. bilateral tubal occlusion or hysterectomy
  9. Willingness and ability to comply with study procedures, visit schedules, study restrictions, and requirements.

Exclusion criteria

Exclusion Criteria:

  1. The patient has participated in any other /interventional trial including an investigational drug within 30 days (or five half-lives of the study drug prior to screening, whichever is longer) prior to screening.
  2. Diagnosis of malignant disease within the previous 5 years (excluding basal cell carcinoma of the skin without complications, "in-situ" carcinoma of the cervix or breast, or other local excised or irradiated with a high probability of cure).
  3. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
  4. The patient has a history of alcohol abuse or drug abuse within the past 12 months.
  5. Any condition including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study.
  6. Lack of suitability for participation in the study, for any reason, judged by the Investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Active comparator
    Azacitidine

    Treatment phase 1: the patients will receive regular treatment with azacitidine for 4 days. Treatment phase 2: the patients will receive regular treatment with azacitidine for 3 days.

    Drug: Azacitidine Injection

  • Experimental
    NEX-18a

    Treatment phase 1: the azacitidine dose for day 5 will be replaced by a single dose NEX-18a Treatment phase 2: the azacitidine dose for day 4 and 5 will be replaced by a single dose NEX-18a

    Drug: NEX-18a injection

Interventions

  • In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection. In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection.

    Also known as: PharmaShell, Azacitidine, 5-azacitidine

  • In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.

    Also known as: Azacitidine, 5-azacitidine, Vidaza

06

What researchers measure

Primary outcomes

  1. Hematology and Clinical Chemistry analyses

    Change from baseline to 30 days follow-up. Descriptive individual data.

    Time frame: 0-30 days

  2. Adverse events

    Change from baseline to 30 days follow-up. Descriptive individual data.

    Time frame: 0-30 days

  3. Vital signs

    Change from baseline to 30 days follow-up. Descriptive individual data.

    Time frame: 0-30 days

  4. Physical examination

    Change from baseline to 30 days follow-up. Descriptive individual data.

    Time frame: 0-30 days

  5. Local tolerance (injection site)

    Change from baseline to 30 days follow-up. Descriptive individual data.

    Time frame: 0-30 days

  6. Concomitant medications/therapy

    Change from baseline to 30 days follow-up. Descriptive individual data.

    Time frame: 0-30 days

Secondary outcomes

  1. AUC-time curve

    From time 0 to 24 hours

    Time frame: 0-24 h

  2. AUC from time 0-last

    From time 0 to last

    Time frame: 0-336 h

  3. AUC from time 0 to infinity

    From time 0 to infinity

    Time frame: 0-336 h

  4. Plasma Concentration

    Maximum Plasma Concentration

    Time frame: 0-336 h

  5. Plasma Concentration over time

    Plasma Concentration at 336h

    Time frame: 0-336 h

  6. Half-life measurement

    Terminal elimination half-life

    Time frame: 0-336 h

  7. Measurement of distribution

    Volume of distribution

    Time frame: 0-336 h

  8. Elimination

    Clearance

    Time frame: 0-336 h

  9. Local tolerance of NEX-18a

    Change from baseline to 30 days follow-up. Descriptive individual data. The local tolerance will be measured by inspection of injection sites. Pain, tenderness erythema/redness, and induration/swelling will be assessed by a four-grade scale where 1 is mild and 4 is potentially life threatening.

    Time frame: 0-30 days

07

Study locations

2 sites
  • Karolinska University Hospital Huddinge
    Huddinge, Sweden
  • Kliniska Forsknings och Utvecklings Enheten KFUE
    Uppsala, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Feb 2022, 9 months.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 9 months is below that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
Sep 17, 2021
StartActual
Apr 27, 2021
Primary completionActual
Feb 10, 2022
CompletionActual
Feb 10, 2022
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05048498
Lead sponsor
Nanexa AB
Collaborators
Uppsala University
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Apr 27, 2021
Primary completion
Feb 10, 2022
Completion
Feb 10, 2022
Last update
Oct 17, 2023

Study contacts

Ulla Olsson Strömberg, MD
principal investigator · Uppsala University, Uppsala, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion